| 摘要 |
PROBLEM TO BE SOLVED: To modify GLP-1, exendin 3, exendin 4 and other insulinotropic peptides to impart long lasting activity in vivo while keeping their low toxicity and merits in treatment. SOLUTION: The modified insulinotropic peptides consisting of exendin-4(1-39)-Lys<SP>40</SP>(<SB>ε</SB>-MPA)-NH<SB>2</SB>, the modified insulinotropic peptides consisting of exendin-4(1-39)-Lys<SP>40</SP>(<SB>ε</SB>-AEEA-MPA)-NH<SB>2</SB>, a conjugate containing the modified insulinotropic peptides linked to a blood component in a covalent bond, and a conjugate wherein the blood component is serum albumin are provided. COPYRIGHT: (C)2009,JPO&INPIT
|
